DDInter1773 DDInter1082
Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Tesamorelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Tesamorelin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose
Tesamorelin may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin